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Objectives: Several technologies are currently being developed for better 
stratifying individuals at risk of developing Rheumatoid Arthritis (RA) to patient-
tailored treatment. We assessed the potential cost-effectiveness of four technolo-
gies (MRI, il6-serum test, RNA B-cell signature, genetic assay) applied to patients 
with intermediate risk for RA (3-5 points on ACR/EULAR) using an one-year hori-
zon. MethOds: The cost-effectiveness was simulated with a decision model 
using data from the Rotterdam Early Arthritis Cohort (prevalence of RA: 55%). 
The comparator was 2010 ACR/EULAR classification criteria. Test properties (sen-
sitivity (se), specificity (sp) and costs) were based on literature and expert opinion. 
Patients were classified true positive (TP) if they score > = 6 points on the criteria 
or were test positive and used MTX at 12 months. True negative (TN) patients were 
those who that scored < 6 points or were test negative and did not use MTX at 
12 months. Utility changes within one year were assigned to TP (+0.1), TN (+0.1), 
false positive (+0.05), and false negative (-0.05). Results: RNA B-cell signature 
(se: 0.60; sp: 0.90; costs: € 150) has the largest net benefit (Δ TP-Δ FP) (45%) and is 
most cost-effective with an incremental cost effectiveness ratio (ICER) of € 13,939. 
The il-6 serum test (se 0.70; sp: 0.53; costs: € 100) has an ICER of € 17,343. The MRI 
and genetic assay have ICERs of € 38,541 and € 70,347 due to the higher incremen-
tal costs of these strategies. To stay below a willingness to pay (WTP) threshold 
of € 20,000/QALY gained (given current utility assumptions), the extra test costs 
of the new test strategy can maximally be € 230. cOnclusiOns: The RNA B-cell 
signature or il6-serum tests have most potential to be cost-effective in patients 
with intermediate risk of developing RA.
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Objectives: Rheumatoid arthritis is a progressive inflammatory disease that 
affects greatly patients’ quality of life and demands for aggressive manage-
ment early on during the course of the disease. The emergence of biologics has 
equipped rheumatologists with evolutionary treatment tools but it has also influ-
enced the costs of the disease, thus highlighting the necessity of cost-effective-
ness data. In this light, the purpose of this study was to conduct a systematic 
review of cost-effectiveness data for abatacept i.v. in the treatment of moderate 
to severe rheumatoid arthritis. MethOds: Pubmed, the International Society 
for Pharmacoeconomics and Outcomes Research Outcomes Research Digest, 
the National Health System Economic Evaluation Database, and the Database 
of Abstracts of Reviews of Effects were searched for papers published in the last 
decade (2002-2012). An initial search using the keywords “abatacept, cost effec-
tiveness, and rheumatoid arthritis” was followed by a search of related citations. 
The quality of independent economic evaluation studies was evaluated in accord-
ance to the Centre for Reviews and Dissemination set of guidelines. Results: In 
total 301 studies were identified and 42 met the inclusion criteria. The majority 
of rejected studies were due to lack of cost data, failure to include abatacept as 
a comparator to other biologic agents, and failure to include RA as a treatment 
indication. Half of the selected studies evaluated abatacept in the treatment 
of rheumatoid arthritis, after failure of or intolerance to tumor necrosis factor 
alpha inhibitors. Of those, 82% were in favor of abatacept as a cost-effective or 
dominant strategy versus varying alternatives, whereas 18% favored other treat-
ments. cOnclusiOns: The majority of evidence from the published literature 
supports that abatacept IV can be a cost-effective alternative in the treatment of 
moderate to severe rheumatoid arthritis.
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Objectives: To assess the cost-effectiveness of tocilizumab and TNF-alfa inhibi-
tors in the treatment of Russian patients with rheumatoid arthritis (RA) and 
intolerance or inadequate response to disease-modifying antirheumatic drugs 
(DMARDs) or for whom continuation of DMARDs was deemed inappropri-
ate. MethOds: Based on the data from ADACTA-trial and the results of indirect 
comparison of tocilizumab and anti-TNF-alfa agents (G. Bergman et al., 2010) 
two pharmacoeconomic models were developed. A six-month time horizon was 
adopted in the models. Cost-effectiveness of tocilizumab and adalimumab was 
estimated in the first model. In the second model, cost-effectiveness of toci-
lizumab was compared to the cost-effectiveness of antirheumatic therapy in 
the mixed treatment group, which included patients who received infliximab, 
etanercept and adalimumab in proportion 1:1:1. The cost analysis included 
costs of medicines and expenses for the day care services. The efficacy of the 
treatment was defined as a DAS28-reduction, proportion of patients achieved 
a low or moderate DAS28, EULAR good or moderate response (was considered 
only in the first model) and ACR20, ACR50, ACR70 responses. Sensitivity analysis 
(SA) was performed by changing costs of medicines and relative proportions of 
patients received infliximab, etanercept and adalimumab in the mixed treat-
ment group. Results: Despite the higher cost of treatment with tocilizumab 
(591,112.92 RUB as compared to 488,735.00 RUB for adalimumab), it had the bet-
ter cost-effectiveness ratios (CERs): 179,125.04 RUB vs 271,519.44 RUB per unit of 
DAS28-reduction, respectively. The similar results were observed for the CERs 
estimated per one patient with clinical response. Compared to the mixed treat-
ment group, tocilizumab also had better CERs. SA confirmed the robustness of 
the model. cOnclusiOns: The study has demonstrated that tocilizumab is an 
economically effective strategy in the treatment of Russian patients with RA 
and intolerance or inadequate response to DMARDs or for whom continuation 
of DMARDs was deemed inappropriate.
with the lowest total costs (437,620.24 RUB per one patient). The costs further 
increased in the row: etanercept (554,912.15 RUB), adalimumab (977,470.00 RUB), 
and infliximab (1,039,363.68 RUB). It should be noted that in the infliximab group 
the bulk of the costs (more than 60% of total) incurred within first six month of 
therapy. This may potentially increase the financial losses associated with inad-
equate response to infliximab. The estimated cost-effectiveness ratios (CERs) were 
241,779.14 RUB, 334,284.43 RUB, 630,625.81 RUB, and 670,557.21 RUB per unit of 
DAS28-reduction in the rituximab, etanercept, adalimumab and infliximab groups, 
respectively. The similar results were observed for the CERs estimated per one 
patient with EULAR good or moderate response (533,683.22 RUB, 730,147.57 RUB, 
1,286,144.74 RUB, and 1,367,583.79, respectively). SA demonstrated that results are 
robust. cOnclusiOns: The present study has demonstrated that administration 
of rituximab is economically effective strategy in the treatment of Russian patients 
with rheumatoid arthritis who failed previous anti-TNF-alfa therapy. Furthermore, 
treatment with rituximab is associated with considerably lower costs as compared 
to etanercept, adalimumab and infliximab.
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Objectives: Assess the cost-effectiveness of first-line tocilizumab bio-
logical treatment as monotherapy or in combination with methotrexate, in 
patients with rheumatoid arthritis (RA) refractory to treatment with non-
biological DMARDs. MethOds: A markov model was used of the natural his-
tory of RA to assess: tocilizumab, tocilizumab+methotrexate, adalimumab, 
adalimimab+methotrexate, etanercept, etanercept + methotrexate and 
infliximab+methotrexate. The systematic review of literature don’t show results 
for infliximab in monotherapy. The strategies were evaluated in combination with 
methotrexate in the first or second line, for a total of 11 strategies evaluated. 
Outcomes were measured as quality adjusted life years (QALYs). Analysis from 
the payer perspective, only direct costs were considered, COP 2012. Ratios were 
calculated cost-effectiveness and incremental cost-effectiveness, and sensitivity 
analyzes deterministic and probabilistic were conducted. For the RA chronicity, 
was used time horizon until life expectancy used discount rate of 3% for both costs 
and health outcomes. Results: Tocilizumab was one of the least expensive strat-
egy in first and second-line treatment. For life expectancy horizon monotherapy 
with tocilizumab followed by infliximab in second line are efficient frontier with 
an ICER per QALY gained of COP $165,918,610.58. The ICER is sensible to price 
of medicaments, with a inferiority limit, the results change to COP $106.160.64. 
The probabilistic analysis indicates that a threshold to willingness to pay of COP 
$ 150 million higher than monotherapy with tocilizumab, be cost-effective in 
Colombia. cOnclusiOns: The use of tocilizumab in first and second line like 
monotherapy and in combination strategy remains lower costs per benefit gained; 
in that sense, can be considered as an efficient therapy in the Colombian context.
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Objectives: The prognosis of rheumatoid arthritis (RA) has improved dramati-
cally with the development of tumour necrosis factor-alpha (TNFα ) inhibitors. 
However, some patients develop immunogenicity to TNFα inhibitors that can result 
in treatment failure and higher costs. In addition, immunogenicity to one TNFα 
inhibitor may create cross-resistance to others. Previous studies have shown the 
TNFα inhibitor etanercept (ETN) is less immunogenic than adalimumab (ADA) and 
infliximab (INF). The objective of this study was to determine the costs incurred 
due to the immunogenicity of ETN, ADA, and INF. MethOds: A Markov model 
was created using data from previously published studies (i.e. the proportions 
of patients developing antibodies against ADA and INF; the size of increase of 
dose or drug administration frequency in patients receiving ADA and INF if treat-
ment failed; and the rate of effective dose escalation in patients with and without 
immunogenicity) and from expert opinion (i.e. physician visit intervals). It was 
assumed that patients receiving ETN did not develop immunogenicity. Patients 
initially started ETN, ADA, or INF were allowed to switch treatment to a second 
or third TNFα inhibitor if treatment failed. Costs due to immunogenicity were 
calculated from: drug usage after treatment failure, dose or frequency increase 
after treatment failures, and additional visits due to lack of response. Results: 
Initiating treatment with ETN resulted in the highest proportion of patients still 
receiving first-line therapy after 5 years, compared with ADA or INF. Assuming 
15,000 patients (1% prevalence of RA in The Netherlands) treated for 5 years, 
the immunogenicity costs incurred with different sequential treatment strat-
egies were: ETN-ADA-INF € 4,937,176, ETN-INF-ADA € 5,409,593, ADA-ETN-INF 
€ 10,140,206, INF-ETN-ADA € 11,160,699, ADA-INF-ETN € 14,735,996, and INF-ADA-
ETN € 15,980,783. cOnclusiOns: The 5-year results of our model showed initiat-
ing treatment with ETN rather than ADA or INF resulted in higher adherence to 
first-line therapy and lower immunogenicity costs.
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